Crisaborole

(Eucrisa®)

Eucrisa®

Drug updated on 11/13/2023

Dosage FormOintment (topical; 2%)
Drug ClassPhosphodiesterase 4 inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Eucrisa (crisaborole) Prescribing Information.2020Pfizer Labs, New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Guidelines of care for the management of atopic dermatitis.2023Journal of the American Academy of Dermatology
Guidelines for the Management of Atopic Dermatitis in Children: A Systematic Review.2023International Archives of Allergy and Immunology
First update of the living European guideline (EuroGuiDerm) on atopic eczema.2023Journal of the European Academy of Dermatology and Venereology
Clinical practice guidelines for the diagnosis and management of atopic dermatitis.2021Asian Pacific Journal of Allergy and Immunology